Company Enters Into License, Commercialization and Supply Agreement Company to Host Conference Call at 12:30 p.m. Eastern Time, September 19,
LEXINGTON, Mass., Sept. 19 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with Allergan's acquisition of Esprit Pharma, Indevus has executed an amended and restated license, commercialization and supply agreement with Esprit Pharma that will be effective, with certain exceptions, on the closing of the acquisition. The acquisition of Esprit Pharma is expected to be completed by the end of October 2007. The Company will host a conference call and webcast today at 12:30 p.m. eastern time (details follow below).
"We are extremely pleased to see SANCTURA XR now in the hands of a
company with the resources and experience to maximize what we believe is a
class- leading opportunity" said Glenn L. Cooper, M.D., chief executive
officer and chairman of Indevus. "Allergan has a proven record of success
in marketing specialty pharmaceuticals, and with their leadership I am
quite optimistic that SANCTURA XR will be in a strong position to achieve
its full potential. We look forward to working with Allergan over the
coming months to prepare for a successful launch of SANCTURA XR and upon
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved